PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-57.23%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-57.23%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
5.53%
Positive EBIT growth while AGEN is negative. John Neff might see a substantial edge in operational management.
5.53%
Positive operating income growth while AGEN is negative. John Neff might view this as a competitive edge in operations.
5.62%
Positive net income growth while AGEN is negative. John Neff might see a big relative performance advantage.
13.79%
Positive EPS growth while AGEN is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
13.79%
Positive diluted EPS growth while AGEN is negative. John Neff might view this as a strong relative advantage in controlling dilution.
10.10%
Share count expansion well above AGEN's 11.27%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
10.10%
Diluted share count expanding well above AGEN's 11.27%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
18.75%
Positive OCF growth while AGEN is negative. John Neff would see this as a clear operational advantage vs. the competitor.
17.73%
Positive FCF growth while AGEN is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1028.36%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
94.36%
Positive OCF/share growth while AGEN is negative. John Neff might see a comparative advantage in operational cash viability.
80.21%
3Y OCF/share CAGR above 1.5x AGEN's 14.19%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
-551.14%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
94.20%
Positive 5Y CAGR while AGEN is negative. John Neff might view this as a strong mid-term relative advantage.
81.22%
Positive short-term CAGR while AGEN is negative. John Neff would see a clear advantage in near-term profit trajectory.
1992.70%
Positive growth while AGEN is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
-67.70%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-15.48%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
12.46%
Positive asset growth while AGEN is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
3.36%
Positive BV/share change while AGEN is negative. John Neff sees a clear edge over a competitor losing equity.
-16.56%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-15.08%
Our R&D shrinks while AGEN invests at 8.72%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-0.47%
We cut SG&A while AGEN invests at 1.82%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.